|
|
 |
Get a job periactin buy
"Today's decision represents a material setback to Novartis's beleaguered vaccine division. In the absence of a successful appeal, Bexsero revenue will likely be restricted to a minimal private-payer market," Citi analyst Andrew Baum said.
2021-2-10 3:31:33 |
|
|
|
